By Chris Wack
ADMA Biologics shares were 15% higher, at $25.25, after the company said the Food and Drug Administration approved its innovative yield-enhancement production process.
The shares hit their 52-week high of $25.67 earlier in the sesison, and are up 278% in the past 12 months.
The biopharmaceutical company said this process has demonstrated an ability to increase production yields by 20% from the same starting plasma volume.
ADMA Biologics makes products that start out as donated plasma. From the plasma donations, the company extracts immunoglobulin, or antibodies, capable of blocking specific viruses. Its products infuse people with primary immunodeficiency with the virus-blocking antibodies their own bodies can't make.
The company expects the FDA's approval to speed up its revenue and earnings trajectory, beginning later this year.
ADMA says the new yield process will benefit its Bivigam and Asceniv antibody products.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 28, 2025 09:58 ET (13:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.